Travoprost Implant for Glaucoma or Ocular Hypertension
This study is testing a new way to treat glaucoma (a group of eye conditions that damage the optic nerve) or ocular hypertension (high pressure inside the eye). It's comparing a second-generation Travoprost Intracameral Implant to Timolol eye drops 0.5%. The implant is a small device placed in the eye that releases the drug Travoprost. Researchers want to see how safe and effective the implant is at lowering eye pressure. You might be able to join if you are 18 or older and have open-angle glaucoma or ocular hypertension in the eye being studied. The main goal is to measure your eye pressure after 3 months.
- Study design
- This interventional study plans to enroll 510 participants. It compares the Travoprost implant to Timolol eye drops, a sham procedure, or placebo eye drops.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your eye pressure will be measured at 3 months to see how well the treatment worked.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Intraocular pressure (IOP)3 months
Change from baseline in diurnal IOP in the study eye at 8am and 10am at each of Day 11, Week 6, and Month 3 visits